Mr. Little brings over 20 years of medical device marketing and commercial experience in interventional cardiology having served in leadership roles at Abbott Vascular, St. Jude Medical, Bard, and Boston Scientific. He currently serves as Chief Operating Officer at Neovasc, a company disrupting the field of refractory angina focused on improving coronary physiology and alleviating chest pain. As DVP of Global Marketing, and Head of Customer and New Market Insights at Abbott Vascular, Mr. Little was responsible for products accounting for $3B in annual global revenue. While at St. Jude Medical, Mr. Little oversaw the Interventional Cardiology and Structural Heart franchises including the imaging and physiology businesses. Mr. Little began his medical device career and spent 13 years at Boston Scientific.

Dr. Candreva from the University Hospital of Zürich presented the pre-clinical experience with the PyCath system.

Very proud to announce that the Innosuisse project PyC+ "Enhanced blood flow and pressure measurements with PhysioCath- microcatheter for reliable diagnosis of 'Ischemia with Non-Obstructive Coronary Artery' (INOCA)" was accepted for a grant. This will allow the consortium formed by The University Hospital of Zürich, CardioCantro Ticino, ZHAW and Medyria to bring forward the PhysioCath project through further technical development and pre-clinical validation. We are really looking forward to starting this journey.

Medyria hired Thoedoros Pantazoupolos as expert developer of Artificial Intelligence algorithms.